Race Oncology doses first patient in phase 1b/2 AML trial of FluCloZan

pallavi123- August 9, 2021 0

Race Oncology has dosed the first patient in the phase 1b/2 trial of its Zantrene (bisantrene dihydrochloride) in combination with Fludarabine and Clofarabine (FluCloZan) in ... Read More

AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study

pallavi123- June 13, 2021 0

AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More

LUMAKRAS FDA approval : Amgen bags approval in KRAS G12C-mutated NSCLC

pallavi123- May 29, 2021 0

LUMAKRAS FDA approval : Amgen has bagged accelerated approval from the US Food and Drug Administration (FDA) for LUMAKRAS (sotorasib) for the treatment of a ... Read More

Chronos-3 trial results : Aliqopa, rituximab combo meets primary endpoint of PFS, says Bayer

pallavi123- April 11, 2021 0

Chronos-3 trial results : Bayer said that the investigational combination of Aliqopa (copanlisib) and rituximab considerably increased progression-free survival (PFS) in patients having relapsed indolent ... Read More

Pyxis Oncology raises $152m in Series B round for cancer therapies

pallavi123- March 30, 2021 0

Pyxis Oncology, a Boston-based biotech company, has raised $152 million in a Series B financing round co-led by Arix Bioscience and RTW Investments. The company ... Read More

BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults

pallavi123- March 28, 2021 0

Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma (idecabtagene ... Read More

French biotech company Step Pharma raises €35m in a Series B round

pallavi123- March 24, 2021 0

Step Pharma has raised €35 million in a Series B financing round for advancing STP938, its lead CTPS1 inhibitor into clinical development for the treatment ... Read More

Aura Biosciences raises $80m for VDC therapies for cancers

pallavi123- March 22, 2021 0

Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round for developing virus-like drug conjugate (VDC) therapies ... Read More

Anixa Biosciences files IND with FDA for ovarian cancer CAR-T therapy

pallavi123- March 22, 2021 0

Anixa Biosciences said that it has filed an investigational new drug (IND) application for its ovarian cancer CAR-T therapy with the US Food and Drug ... Read More

Amgen to acquire Five Prime Therapeutics for gastric cancer candidate bemarituzumab

pallavi123- March 4, 2021 0

Amgen acquisition of Five Prime Therapeutics : Amgen has agreed to acquire Five Prime Therapeutics, a clinical-stage biotech company, for about $1.9 billion, to add ... Read More